William Blair Has Weak Estimate for QuidelOrtho Q2 Earnings

Key Points

• William Blair has reduced its earnings estimates for QuidelOrtho's Q2 2026 to $0.25 per share, down from $0.26, while the consensus estimate for the full year remains at $2.30 per share.
• The company reported a Q2 earnings of $0.12 per share, surpassing analysts' expectations, but noted a negative net margin of 16.10% and a 3.6% decline in revenue compared to the same period last year.
• QuidelOrtho's stock has received mixed ratings from analysts, with a current consensus rating of "Hold" and target prices ranging from $26.00 to $40.00.

QuidelOrtho Corporation (NASDAQ:QDEL - Free Report) - Stock analysts at William Blair cut their Q2 2026 earnings estimates for shares of QuidelOrtho in a report released on Wednesday, October 8th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of $0.25 per share for the quarter, down from their previous forecast of $0.26. The consensus estimate for QuidelOrtho's current full-year earnings is $2.30 per share. William Blair also issued estimates for QuidelOrtho's Q4 2026 earnings at $0.98 EPS and FY2026 earnings at $2.67 EPS.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.11. QuidelOrtho had a negative net margin of 16.10% and a positive return on equity of 5.29%. The firm had revenue of $613.90 million during the quarter, compared to analysts' expectations of $612.36 million. During the same period in the previous year, the business posted ($0.07) earnings per share. The company's revenue for the quarter was down 3.6% compared to the same quarter last year.

A number of other equities research analysts also recently weighed in on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of QuidelOrtho in a research report on Wednesday. Citigroup reaffirmed a "neutral" rating and set a $33.00 price target (down from $40.00) on shares of QuidelOrtho in a report on Tuesday. Wall Street Zen lowered QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. Finally, UBS Group cut their target price on QuidelOrtho from $29.00 to $26.00 and set a "neutral" rating on the stock in a report on Thursday, August 7th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $37.80.

QuidelOrtho Trading Up 0.7%

Shares of QuidelOrtho stock opened at $28.06 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 1.12. The firm has a 50-day moving average of $27.49 and a 200-day moving average of $28.71. QuidelOrtho has a 52-week low of $22.05 and a 52-week high of $49.45. The stock has a market cap of $1.91 billion, a PE ratio of -4.29 and a beta of 0.27.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bfsg LLC grew its holdings in QuidelOrtho by 6.8% in the second quarter. Bfsg LLC now owns 5,460 shares of the company's stock worth $157,000 after purchasing an additional 347 shares during the period. Quarry LP boosted its position in shares of QuidelOrtho by 47.1% during the 1st quarter. Quarry LP now owns 1,436 shares of the company's stock worth $50,000 after purchasing an additional 460 shares in the last quarter. Yousif Capital Management LLC grew its stake in shares of QuidelOrtho by 1.8% in the 2nd quarter. Yousif Capital Management LLC now owns 26,428 shares of the company's stock valued at $762,000 after buying an additional 478 shares during the period. Texas Permanent School Fund Corp increased its position in QuidelOrtho by 1.9% in the 2nd quarter. Texas Permanent School Fund Corp now owns 30,379 shares of the company's stock valued at $876,000 after buying an additional 578 shares in the last quarter. Finally, Blue Trust Inc. increased its position in QuidelOrtho by 46.4% in the 2nd quarter. Blue Trust Inc. now owns 1,967 shares of the company's stock valued at $57,000 after buying an additional 623 shares in the last quarter. Institutional investors and hedge funds own 99.00% of the company's stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.